Prakiraan wutah bathi kanggo taun ngarep: IGC Pharma (IGC)

The trend of consensus EPS forecasts for the coming year on the GURU.Markets chart shows that 19.70 is the current value of the indicator. Growth for IGC Pharma, Inc. (IGC) is driven by IGC-AD drug trials and AI implementation. However, a lack of revenue and legal complexities create significant risks. Meanwhile, IGC Pharma, Inc. (IGC) complies with environmental regulations, minimizing the impact of laboratory waste.
India Globalization Capital - rincian analitis lan metrik utama (IGC)

This metric reflects the dynamics of expected earnings per share, filtering out market noise to assess the business's fundamental resilience to external shocks. By analyzing the forward EPS forecast for the coming year, investors can see how the capitalization of IGC Pharma, Inc. (IGC) depends on the outcome of clinical trials for cannabinoid drugs. The high volatility of this metric confirms the speculative nature of the assets, where profit growth is directly tied to regulatory decisions.